Abstract
Lacto-N-neotetraose (LNnT) is a crucial neutral core human milk oligosaccharide (HMO). In this study, we established a LNnT-producing Saccharomyces cerevisiae cell factory through comprehensive metabolic engineering. Specifically, the de novo biosynthetic pathway of LNnT was assembled by heterologously expressing the lactose permease (Lac12) from Kluyveromyces lactis and the glycosyltransferase from Neisseria meningitidis in Saccharomyces cerevisiae. Subsequently, carbon source regulation based on the glucose-sensitive GAL regulatory system was employed to optimize the expression time of heterologous genes, achieving a production of 15.61 mg/L of LNnT in shake-flask fermentation. In addition, the key rate-limiting steps involved in LNnT synthesis pathway were identified and the corresponding genes were overexpressed to enhance LNnT production, resulting in an eight-fold increase in LNnT titer compared to that of parental strain. To our knowledge, this is the first report on LNnT biosynthesis in Saccharomyces cerevisiae, opening up the possibility of green production of LNnT using food-safe microorganisms.
Introduction
Human milk oligosaccharides (HMOs) are the third most abundant solid component in breast milk and are essential for infant health, supporting immune system development and healthy gut flora. LNnT is a key "neutral" HMO that is increasingly sought after as an additive for infant formula. Currently, sourcing LNnT is difficult; extraction from human milk is impossible at scale, and chemical synthesis is expensive and complex. While microbial fermentation using E. coli has been successful, these bacteria can produce endotoxins, complicating their use in food. Saccharomyces cerevisiae is a "Generally Recognized as Safe" (GRAS) organism, making it an ideal "cell factory," though it does not naturally possess the machinery to import lactose or synthesize LNnT.
Metabolic Engineering Strategy
To enable LNnT production, researchers employed a multi-pronged metabolic engineering strategy centered on pathway assembly and dynamic regulation. Since yeast cannot naturally metabolize lactose—a core building block for LNnT—they introduced the Lac12 gene (lactose permease) from Kluyveromyces lactis. They then added two bacterial genes (lgtA and lgtB) from Neisseria meningitidis to catalyze the assembly of LNnT from lactose and internal precursors (UDP-GlcNAc and UDP-Gal).
The researchers divided the metabolic network into three modules to streamline optimization:
- Module 1 (M1): The heterologous pathway (lactose import and final assembly).
- Module 2 (M2): The supply of UDP-Galactose.
- Module 3 (M3): The supply of UDP-N-acetylglucosamine.
To prevent metabolic overload, the team used a glucose-sensitive GAL regulatory system. By knocking out the GAL80 gene, they created a system where high glucose levels inhibit production during the growth phase, but as glucose is consumed, the LNnT-producing genes "switch on" automatically, decoupling growth from production.
Results and Key Insights
Initial trials identified that getting lactose into the cell is a major rate-limiting step. While overexpressing the lactose permease (Lac12) boosted yields, doing so via plasmids caused high metabolic stress. By moving to chromosomal integration of key rate-limiting genes in Modules 2 and 3, the team achieved a massive jump in performance.
Key findings from the study include:
- Titer Breakthrough: The final engineered strains reached titers between 121.97 mg/L and 145.91 mg/L, representing an approximate eight-fold increase over the initial engineered strains.
- Efficient Secretion: Nearly 93% of the produced LNnT was found in the extracellular broth. This is a significant industrial advantage, as it simplifies the purification process compared to intracellular accumulation.
- Module Hierarchy: While all modules contributed, the heterologous genes in Module 1 were the primary factors influencing production, with M2 and M3 providing essential supporting roles.
Conclusion and Future Work
This research represents the first reported biosynthesis of LNnT in S. cerevisiae, providing a foundational blueprint for using food-safe yeast to produce high-value human milk components. While current titers are lower than those in E. coli systems, the authors suggest that future work focusing on enzyme screening for better-suited glycosyltransferases and further pathway expansion will move the industry closer to accessible, "humanized" infant nutrition.
Summary updated